

Bora Pharmaceuticals Reports Consolidated Revenue of NT\$1.72 Billion in September

保瑞公告 9 月自結合併營收新台幣 17 億 2 仟萬元

Taipei, Taiwan, October 9, 2025 – Bora Pharmaceuticals Co., Ltd. (“Bora” or “the Company”) announced that its consolidated revenues for September 2025 reached NT\$1.72 billion, a decrease of 15.0% compared to same period last year but a 25.8% rebound from August. The continued weakness of the U.S. dollar negatively impacted revenue by approximately NT\$100 million during the month. In functional currency terms (USD), September revenues ranked as the third highest this year, representing an accumulated year-to-date growth of 11.8% over last year.

台北，台灣，2025 年 10 月 9 日 – 保瑞藥業（以下簡稱「保瑞」，股票代碼：6472）今日公告 9 月自結合併營收為新台幣 17 億 2 仟萬元，較去年同期衰退 15.0%但較前一月回溫 25.8%，持續疲弱的美元影響營收約新台幣 1 億元；若以功能性貨幣美金計，9 月營收為今年第三高，累計較去年增長 11.8%。

The CDMO business maintained its upward momentum in September, driven by a steady increase in filled batches at the Maryland fill/finish facility compared to 2024. It is worth noting that mass production on the new Flex Pro line began in September, marking a key milestone supported by an anchor client. Amid the growing onshoring wave, the demand for US fill-finish production has become a clear wedge of differentiation and strategic focus. Switching gear, Bora plans to have its high-potency liquid capsule manufacturing capabilities available for customers at Zhunan facility in Q1 of 2026. A new operational area has been designed at the facility to support the expansion, which will address the growing demand for stable delivery of sensitive compounds and complex pharmaceutical ingredients, such as oncology or potent drugs. The facility currently supplies drug products to the United States, Taiwan, and throughout Asia, reinforcing its role as a trusted global supply hub.

CDMO 業務延續 8 月的動能持續增長，馬里蘭州針劑廠產量已超越去年，Flex Pro 新產線的客戶亦已投產；在美國製造聲浪中，針劑充填的在地製造需求尤為明確，是保瑞提前布局差異化製造的里程碑。而竹南廠新增的液體膠囊生產區域已完成設計，因應市場對於穩定傳遞高敏感度與複雜性原料（如腫瘤藥物或高活性藥品）劑型的需求日益提升，預計 2026 年第一季進入量產。該廠區目前已取得美國 FDA 與英國 MHRA 等國際藥政機關認證，並穩定供應美國、台灣及亞洲多國市場，在保瑞全球供應網絡中仍具關鍵地位。

In September, pharma sales regained momentum. While the generic drug market remains highly competitive, the specialty portfolio, anchored by Vigabatrin franchise, continued to post solid growth. As certain generic products transition to contract manufacturing outside the U.S., product mix optimization is expected to further improve gross margin. The Company continues to view regulatory approval of its high value generic products in the fourth quarter as a key driver for subsequent growth in the generic segment.

而全球銷售業務已於 9 月恢復正常供貨，雖然學名藥的壓力仍大，以 Vigabatrin 為首的專科用藥系列增

長強勁，預期隨著部分自售學名藥藥品自美國轉出生產，產品組合優化有望提升毛利率；而公司仍持續視特殊學名藥第四季取證為學名藥後續成長關鍵。

About Bora:

Founded in 2007, Bora Pharmaceuticals ("Bora" or "the Company", 6472.TW) is a leading pharmaceutical services company with a vision and goal of "Contributing to Better Health All Over the World". Operating under a "Dual Engine" model that integrates CDMO and commercial expertise, we empower pharmaceutical and biotech partners to optimize product development, accelerate launches, and scale supply to meet global patient needs. At the same time, we actively broaden R&D and sales infrastructure, focusing on niche and rare disease markets to improve patients' quality of life.

By investing in talent, infrastructure, and biologics expansion, Bora continues to transform operations and achieve sustainable growth. Committed to making success "certain," Bora sets new standards in the pharmaceutical and CDMO industries.

For more, please visit:

<https://www.bora-corp.com>

<https://www.boracdm.com>

關於保瑞：

保瑞藥業股份有限公司（股票代碼：6472）成立於2007年，是一家領先的製藥服務公司，自成立伊始即秉持「為全世界健康貢獻力量」的願景與目標。保瑞以整合 CDMO（委託開發與製造服務）與藥物開發銷售的「雙引擎」商業模式，協助製藥與生技合作夥伴優化產品開發流程、加速上市時程、擴大供應規模以滿足全球患者的需求。公司亦專注於美國的利基市場及罕見疾病領域，致力於透過拓展銷售通路實力提升患者的生活品質。

透過持續投資人才、生產與銷售及進入生物製劑業務領域，保瑞不斷推動業務升級與永續發展。我們以Making Success More Certain為使命，專注高品質、高效率與可靠性，在製藥及 CDMO 領域樹立新標杆。

請造訪：

企業網站 <https://www.bora-corp.com>

CDMO 網站 <https://www.boracdm.com>

Investor/Media enquiries 新聞聯繫人：

Nadiya Chen, Investor Relations 投資人關係 陳荻雅

+886 2 790-1555 Ext. 9108

Email: Nadiya.Chen@bora-corp.com